245 related articles for article (PubMed ID: 27149663)
21. Realigning incentives for developing and pricing new anticancer treatments.
Howard DH
JAMA; 2011 Jun; 305(22):2347-8. PubMed ID: 21642689
[No Abstract] [Full Text] [Related]
22. Physicians, Accountable Care, And Drugs.
Weil AR
Health Aff (Millwood); 2016 Mar; 35(3):387. PubMed ID: 26953288
[No Abstract] [Full Text] [Related]
23. Making Health Care Markets Work: Competition Policy for Health Care.
Gaynor M; Mostashari F; Ginsburg PB
JAMA; 2017 Apr; 317(13):1313-1314. PubMed ID: 28253376
[No Abstract] [Full Text] [Related]
24. Volume and intensity of Medicare physicians' services: an overview.
Kay TL
Health Care Financ Rev; 1990; 11(4):133-46. PubMed ID: 10113398
[TBL] [Abstract][Full Text] [Related]
25. Sources of the growth in Medicare physician expenditures.
Berenson R; Holahan J
JAMA; 1992 Feb; 267(5):687-91. PubMed ID: 1731136
[No Abstract] [Full Text] [Related]
26. Prescription drug prices in Canada.
Gross D
Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2003 Jun; (IB62):1-22. PubMed ID: 12807123
[No Abstract] [Full Text] [Related]
27. Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer.
Ito K; Elkin E; Blinder V; Keating N; Choudhry N
Cancer; 2013 Jul; 119(13):2494-502. PubMed ID: 23775433
[TBL] [Abstract][Full Text] [Related]
28. Counting Better--The Limits and Future of Quality-Based Compensation.
Dale CR; Myint M; Compton-Phillips AL
N Engl J Med; 2016 Aug; 375(7):609-11. PubMed ID: 27532826
[No Abstract] [Full Text] [Related]
29. Paying for Cancer Drugs That Prove Their Benefit.
Frank RG; Emanuel EJ
JAMA; 2021 Oct; 326(16):1579-1580. PubMed ID: 34633420
[No Abstract] [Full Text] [Related]
30. Reducing Branded Prescription Drug Prices: A Review of Policy Options.
Alexander GC; Ballreich J; Socal MP; Karmarkar T; Trujillo A; Greene J; Sharfstein J; Anderson G
Pharmacotherapy; 2017 Nov; 37(11):1469-1478. PubMed ID: 28805961
[TBL] [Abstract][Full Text] [Related]
31. 340B Drug Pricing Program Reform.
Fong WH
JAMA Oncol; 2016 Mar; 2(3):403. PubMed ID: 26967190
[No Abstract] [Full Text] [Related]
32. Physician Payment after the SGR--The New Meritocracy.
Rosenthal MB
N Engl J Med; 2015 Sep; 373(13):1187-9. PubMed ID: 26398068
[TBL] [Abstract][Full Text] [Related]
33. A piece of my mind. Slippery slopes and landing on your feet.
Huesch MD
JAMA; 2014 Mar; 311(12):1203-4. PubMed ID: 24668099
[No Abstract] [Full Text] [Related]
34. Determining the most economical SSRI for a Medicare risk contract.
Valdez C; Grier D
Am J Health Syst Pharm; 1999 Jan; 56(1):23-4. PubMed ID: 10048874
[No Abstract] [Full Text] [Related]
35. Cost consequences of the 340B drug discount program.
Conti RM; Bach PB
JAMA; 2013 May; 309(19):1995-6. PubMed ID: 23609758
[No Abstract] [Full Text] [Related]
36. 340B Drug Pricing Program Reform-Reply.
Kantarjian H; Chapman R
JAMA Oncol; 2016 Mar; 2(3):403-4. PubMed ID: 26967191
[No Abstract] [Full Text] [Related]
37. Assessing the effects of drug price reduction policies on older people in Taiwan.
Chu HL; Liu SZ; Romeis JC
Health Serv Manage Res; 2011 Feb; 24(1):1-7. PubMed ID: 21285360
[TBL] [Abstract][Full Text] [Related]
38. New Medicare bill targets discrepancies in fees for cancer drugs, outpatient services.
Twombly R
J Natl Cancer Inst; 2004 Feb; 96(3):166-8. PubMed ID: 14759976
[No Abstract] [Full Text] [Related]
39. Limits on Medicare's ability to control rising spending on cancer drugs.
Bach PB
N Engl J Med; 2009 Feb; 360(6):626-33. PubMed ID: 19176475
[No Abstract] [Full Text] [Related]
40. Physicians. Profiling in practice.
Montague J
Hosp Health Netw; 1994 Jan; 68(2):50-1. PubMed ID: 8275129
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
